Cartiva, Inc. Announces Positive FDA Advisory Committee Review Of Cartiva SCI

Cartiva, Inc., (Company) a developer of innovative products for the treatment of cartilage injuries, osteoarthritis and other musculoskeletal conditions, announced recently that the Orthopaedic and Rehabilitation Devices Panel convened by the U.S. Food and Drug Administration (FDA) voted 10 to two in favor of the safety of the Company’s Cartiva Synthetic Cartilage Implant (SCI) for the treatment of osteoarthritis at the base of the great toe, nine to three in favor of the efficacy of Cartiva SCI and eight to two, with two abstentions, that the benefits outweighed the risks.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news